David Thomson
General Counsel bei MANNKIND CORPORATION
Vermögen: 2 Mio $ am 31.03.2024
Profil
David B.
Thomson has held multiple positions throughout his career.
Currently, he is the Secretary, Executive VP & General Counsel at MannKind Corp.
and also holds the position of Vice President at QrumPharma, Inc. In terms of education, Dr. Thomson completed his undergraduate degree in 1990, followed by a graduate degree in 1991, and a doctorate in 1994 from Queen's University.
He later obtained another graduate degree in 1999 from the University of Toronto.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
MANNKIND CORPORATION
0,18% | 21.03.2024 | 493 482 ( 0,18% ) | 2 Mio $ | 31.03.2024 |
Aktive Positionen von David Thomson
| Unternehmen | Position | Beginn |
|---|---|---|
| MANNKIND CORPORATION | General Counsel | 01.01.2002 |
QrumPharma, Inc.
 QrumPharma, Inc. Pharmaceuticals: MajorHealth Technology QrumPharma, Inc. is engaged in developing drug products. It develops inhalation treatments for severe chronic and recurrent pulmonary infections, including Nontuberculous Mycobacterial (NTM) lung disease. The company was founded by Thomas Hofmann and is headquartered in Doylestown, PA. | Corporate Officer/Principal | - |
Ausbildung von David Thomson
| Queen's University | Doctorate Degree |
| University of Toronto | Graduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| MANNKIND CORPORATION | Health Technology |
| Private Unternehmen | 1 |
|---|---|
QrumPharma, Inc.
QrumPharma, Inc. Pharmaceuticals: MajorHealth Technology QrumPharma, Inc. is engaged in developing drug products. It develops inhalation treatments for severe chronic and recurrent pulmonary infections, including Nontuberculous Mycobacterial (NTM) lung disease. The company was founded by Thomas Hofmann and is headquartered in Doylestown, PA. | Health Technology |
